Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
US IPO Week Ahead: Three profitable IPOs and a biotech look to raise $900 million
Analyst IPO Market Commentary
Four IPOs are on
to raise nearly $900 million in the week ahead. Three are profitable, including the fourth-largest offering of 2016 and two companies that grew more than 30% in the MRQ. A biotech with heavy insider buying will also come to market, another IPO in the most active sector of 2016 (39% of deals).
Markets are near all-time highs, 2016 IPOs have outperformed (up 19% on average) and the VIX Volatility Index is at its lowest point since August 2015. Even so, we expect only a moderate pick-up in IPO activity; issuers remain cautious and IPO buyers remain sensitive to valuations.
Renaissance Capital's IPO Calendar - Week of 7/18/2016
$19 - $22
Global provider of contract drug manufacturing and development services.
$15 - $17
Largest independent US manufacturer of composite wind blades.
San Francisco, CA
$14 - $16
BofA Merrill Lynch
Cowen & Company
Preclinical biotech developing gene therapies for rare diseases.
$12 - $14
RBC Capital Markets
Leading provider of radio-frequency identification tags and reader chips.
Tactile Systems Tech
$14 - $16
Sells at-home compression therapy devices for vascular swelling.
$11 - $13
RBC Capital Markets
Developing a novel nonstatin therapy to treat high cholesterol.
Find out why institutional investors rely on Renaissance Capital's
for these IPOs.
Follow us on Twitter (
) for IPO news as it happens and
register for our updates
on the IPO market.
International drug trade: Patheon to go public
) - One of the world's largest contract drug manufacturers is set to raise $625 million in one of the year's largest IPOs. LBO'd in 2013, Amsterdam-based Patheon offers a unique proposition for top pharmas: It develops drug formulations, creates the active ingredients and then provides large-scale manufacturing and packaging. While it expects to generate strong cash flows in a stable and growing industry, Patheon struggled to generate organic growth more recently, and will remain highly levered after the IPO (5.9x LTM adj. EBITDA) thanks to insider distributions. We note that 18 of the 20 IPOs this year that raised over $100 million have a positive return, and an average gain of +33%.
Life of PI: VC-backed tech IPO Impinj
) - The dominant provider of RFID location tags (often used to prevent shoplifting) is set to raise $60 million at a market cap of about $250 million. The company has generated a profit for three consecutive years, and grew sales by 34% to $22 million in the first quarter. Backed by ARCH, Polaris and Intel, Impinj will be only the fourth VC-backed tech IPO of the year, a group that includes 2016's two best-performing deals,
; +187%) and
; +138%). As we noted in our mid-week blog post,
the last 10 tech IPOs have positive returns
, now averaging +56%.
TPI Composites: A new spin on wind blades
) - This former powerboat manufacturer aims to raise $116 million and become the only public pure-play wind blade manufacturer in the US. TPI mainly supplies four large wind turbine companies (93% of revenue), and revenue soared 83% to $586 million in 2015 on strong tailwinds, including an industry shift to outsourcing and clean-energy subsidies. However, as
users know, government benefits are currently up in the air, and set to begin expiring in the US in 2017.
BOLD move from preclinical biotech Audentes
) - Backed by OrbiMed, this gene therapy biotech plans to raise $75 million in the week ahead as it prepares Phase 1 trials for rare diseases. The year's other developer of gene therapies,
), is the best-performing biotech of 2016 (+76%), though other peers
) are down 39% and 52%, respectively, this year. Insiders are taking down up to 40% of the IPO.
Two small-cap healthcare companies,
Tactile Systems Technology
), are still seeking to price their IPOs on a day-to-day basis.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance IPO Index has outperformed the S&P 500 in the past month (+5% vs. +4%), though it has undperformed the S&P year-to-date (-4% vs. +6%). Renaissance Capital's
(NYSE: IPO) tracks the index, and
top ETF holdings
include Alibaba (
), Synchrony Financial (
) and Citizens Financial Group (
). The Renaissance International IPO Index is currently lagging the ACWX on both a 1-month (+1% vs. +4%) and year-to-date (-4% vs. +1%) basis. Renaissance Capital’s International
(NYSE: IPOS) tracks the index, and
top ETF holdings
include Recruit Holdings, NN Group and Aena S.A.
To find out if this is the best ETF for you, visit our
IPO Investing page
Keywords / Tickers:
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds.
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges.
The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE or Nasdaq.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.